Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Two Different Treatments 24 vs 48 Weeks Chronic Hepatitis C Genotypes 2 and/or 3 in co-Infected HIV-HCV

The recruitment status of this study is unknown because the information has not been verified recently.
Verified January 2008 by University of Valencia.
Recruitment status was  Active, not recruiting
Sponsor:
Collaborator:
Hoffmann-La Roche
Information provided by:
University of Valencia
ClinicalTrials.gov Identifier:
NCT00611819
First received: January 25, 2008
Last updated: NA
Last verified: January 2008
History: No changes posted

January 25, 2008
January 25, 2008
November 2005
April 2008   (final data collection date for primary outcome measure)
% of patients with RNA-HCV undetectable 24 weeks [ Time Frame: 24 weeks after the end of treatment ] [ Designated as safety issue: Yes ]
Same as current
No Changes Posted
% of patients at the end of treatment [ Time Frame: 48 weeks of treatmemt ] [ Designated as safety issue: Yes ]
Same as current
Not Provided
Not Provided
 
Two Different Treatments 24 vs 48 Weeks Chronic Hepatitis C Genotypes 2 and/or 3 in co-Infected HIV-HCV
Open, Randomized and Multicenter Phase IV Study to Compare the Efficacy and Safety of Two Different Treatments Duration 24 Versus 48 Weeks in Chronic Hepatitis C Genotypes 2 and/or 3 co-Infected HIV-HCV Patients.

The rapidly progression of the disease in HIV-HCV co-infected patients justify the treatment.

Combination of Peg interferon and Ribavirin is the best treatment because it improve the compliance of treatment.

In APRICOT study genotypes 2 and 3 patients received 48 weeks and the rates of end of treatment response was 64% and the sustained virological response (24 weeks after the end of treatment) 62%.

In mono-infected patients trials showed there are not differences in the sustained virological response between 24 and 48 weeks of treatment, however exit the doubt concerning the different kinetic viral in HIV-HCV co-infected patients and this could be related with a lost of profit with a shorter duration of treatment, only 24 weeks.

In this study we woud like to evaluate if 24 weeks of treatment in HIV-HCV co-infected patients genotype 2 or 3 will have the same rate of clearance of virus at the end of follow-up period.

Patients will randomized to receive 180 µg/weekly of Pef interferon alpha-2a and 800 mg/daily of Ribavirin during 24 weeks or 48 weeks.

Interventional
Phase 4
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Chronic Hepatitis C
  • Co-Infection HIV-HCV
  • Drug: Peg interferon + Ribavirin
    Peg interferon 180 mcg/weekly Ribavirin 800 mg/daily during 24 weeks
    Other Name: Pegasys
  • Drug: Peg interferon + Ribavirin
    Peg interferon alpha 2a 180 mc/weekly Ribavirin 800 mg/daily during 48 weeks
    Other Name: Pegasys
  • Experimental: 1
    Peg interferon alpha 2a 180 mc/weekly Ribavirin 800 mg/daily during 24 weeks
    Intervention: Drug: Peg interferon + Ribavirin
  • Active Comparator: 2
    Peg interferon alpha 2a 180 mc/weekly Ribavirin 800 mg/daily during 48 weeks
    Intervention: Drug: Peg interferon + Ribavirin
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
59
December 2008
April 2008   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Male and female patients of 18-65 years of age
  • Serologic evidence of chronic hepatitis C infection by detectable plasma HCV-RNA
  • Serologic evidence of HIV-1 infection by ELISA and Western-blot
  • Stable status of HIV-1 infection in the opinion of the investigator
  • Negative urine or blood pregnancy test (for women of childbearing potential) documented within the 24-hour period prior to the first dose of study drug. Additionally, all fertile males and females must be using two forms of effective contraception during treatment and during the 6 months after treatment end. This may include, but is not limited to, using birth control pills, IUDs, condoms, diaphragms, or implants, being surgically sterilized, or being in a post-menopausal state.
  • Willingness to give written informed consent and willingness to participate to and comply with the study

Exclusion Criteria:

  • Women with ongoing pregnancy or breast feeding
  • IFN or ribavirin therapy at any previous time
  • Any investigational drug <6 weeks prior to the first dose of study drug
  • History or other evidence of a medical condition associated with chronic liver disease other than HCV
  • Hepatocarcinoma observed
  • History or other evidence of bleeding from esophageal varices or other conditions consistent with decompensated liver disease
  • Active HIV-related opportunistic infection and/or malignancy requiring acute systemic therapy
  • Absolute neutrophil count <1500 cells/mm3
  • Hgb <12 g/dL in women or 13 g/dL in men or any patient for whom anemia would be medically problematic
  • Hemoglobinopathy (e.g. thalassemia) or any other cause of or tendency for hemolysis
  • Platelet count <90000 cells/mm3
  • Serum creatinine level >1.5 times the upper limit of normal at screening
  • History of severe psychiatric disease, especially depression. Severe psychiatric disease is defined as treatment with an antidepressant medication or a major tranquilizer at therapeutic doses for major depression or psychosis, respectively, for at least 3 months at any previous time or any history of the following: a suicidal attempt, hospitalization for psychiatric disease, or a period of disability due to a psychiatric disease
  • History of a severe seizure disorder or current anticonvulsant use
  • History of immunologically mediated disease (e.g., inflammatory bowel disease, idiopathic thrombocytopenic purpura, lupus erythematosus, autoimmune hemolytic anemia, scleroderma, severe psoriasis, rheumatoid arthritis)
  • History or other evidence of chronic pulmonary disease associated with functional limitation
  • History of significant cardiac disease that could be worsened by acute anemia
  • History of thyroid disease poorly controlled on prescribed medications. Patients with elevated thyroid stimulating hormone (TSH) concentrations with elevation of antibodies to thyroid peroxidase and any clinical manifestations of thyroid disease are excluded
  • Evidence of severe retinopathy
  • History of major organ transplantation with an existing functional graft
  • History or other evidence of severe illness, malignancy or any other conditions which would make the patient, in the opinion of the investigator, unsuitable for the study
  • History of any systemic anti-neoplastic or immunomodulatory treatment (including supraphysiologic doses of steroids and radiation) <6 months prior to the first dose of study drug or the expectation that such treatment will be needed at any time during the study
  • Drug use within 6 months of 1st dose and excessive alcohol consumption
Both
18 Years to 65 Years
No
Contact information is only displayed when the study is recruiting subjects
Spain
 
NCT00611819
KHRONOS, 2005-000203-34
No
Enrique Ortega, Hospital General Universitario of Valencia
University of Valencia
Hoffmann-La Roche
Study Director: Enrique Ortega, Dr Hospital General Universitario de Valencia
University of Valencia
January 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP